Analgesics and Anti-inflammatory Drugs Practice Questions

Q: Which of the following opioids can be given intranasally?

Butorphanol. ***Butorphanol*** - **Butorphanol** is a synthetic opioid agonist-antagonist that is commonly available as an **intranasal spray** (Stadols NS) for the treatment of moderate to severe pain, especially for conditions like **migraines** [2]. - Its **high lipid solubility** and **good absorption across nasal mucosa** make it suitable for this route of administration, providing rapid onset of action. - This is the **most well-established and widely used intranasal opioid formulation** in clinical practice. *Tramadol* - **Tramadol** is an opioid analgesic with a primary route of administration that is **oral** or **intravenous**. - It is not typically formulated or administered via the **intranasal route** due to lower bioavailability and potential for local irritation. *Pethidine* - **Pethidine** (meperidine) is an opioid typically given via **intramuscular**, **subcutaneous**, or **intravenous** injection [1]. - It is not formulated for **intranasal use**, and this route would not be an effective or safe delivery method for the drug due to poor absorption and potential for mucosal damage. *Buprenorphine* - **Buprenorphine** is a partial opioid agonist available in various formulations, including **sublingual**, **injectable**, and **transdermal** routes, particularly for opioid dependence treatment and pain management [3]. - While intranasal buprenorphine formulations exist, **sublingual remains the preferred and most commonly used route** in clinical practice due to excellent bioavailability and ease of administration [3]. - **Butorphanol** is the classic intranasal opioid emphasized in medical education.

Q: Which of the following drugs is known for its long-acting effects due to enterohepatic circulation?

Phenylbutazone. ***Phenylbutazone*** - Phenylbutazone is a **long-acting NSAID** with a prolonged half-life of **50-100 hours**. - It undergoes significant **enterohepatic circulation**, where it is excreted in bile, reabsorbed from the intestine, and returned to the systemic circulation. - This enterohepatic recirculation, combined with **extensive protein binding** and slow metabolism, contributes significantly to its prolonged duration of action. - Due to serious adverse effects (bone marrow suppression, aplastic anemia), it is now rarely used in clinical practice. *Sulindac* - Sulindac is a prodrug that does undergo **enterohepatic circulation**. - However, despite this circulation, sulindac has a relatively **short half-life of 7-8 hours** and requires **twice-daily dosing**. - While enterohepatic circulation occurs, it does NOT make sulindac a long-acting NSAID. *Piroxicam* - Piroxicam is a **long-acting NSAID** with a half-life of approximately **50 hours**, allowing for once-daily dosing. - However, its prolonged duration of action is primarily due to its very **slow elimination** and extensive protein binding, NOT significant enterohepatic circulation. *Aspirin* - Aspirin has a relatively **short half-life** (15-20 minutes for the parent drug) and does not undergo significant enterohepatic circulation. - Its prolonged effects on platelets are due to **irreversible COX-1 inhibition**, not extended plasma half-life.

Q: Among NSAIDs, aspirin is unique because it:

Irreversibly inhibits its target enzyme. ***Irreversibly inhibits its target enzyme*** - Aspirin uniquely acetylates a **serine residue** on both **COX-1 and COX-2**, permanently inactivating the enzyme. - This irreversible inhibition is why aspirin's antiplatelet effects last for the lifespan of the platelet (7-10 days), unlike other NSAIDs which are reversible inhibitors. *May reduce the risk of colon cancer* - While some studies suggest a link between long-term aspirin use and reduced colon cancer risk, this is a property shared by some other NSAIDs and is not a unique distinguishing feature of aspirin among NSAIDs. - This effect is generally attributed to the **inhibition of COX-2**, which is involved in tumor growth and inflammation. *Reduces fever* - **Antipyresis** (fever reduction) is a characteristic effect of nearly all NSAIDs, including ibuprofen and naproxen, due to the inhibition of prostaglandin synthesis in the hypothalamus. - Therefore, this is not a unique feature of aspirin. *Selectively inhibits COX-1 enzyme* - Aspirin is a **non-selective COX inhibitor**, meaning it inhibits both COX-1 and COX-2 enzymes at anti-inflammatory doses. - While it has a higher affinity for COX-1 at low doses, drugs like celecoxib are genuinely selective COX-2 inhibitors, and no common NSAID is purely selective for COX-1.

Q: Etanercept, used in rheumatoid arthritis, acts by:

TNF alpha. ***TNF alpha*** - Etanercept is a **fusion protein** that acts as a **decoy receptor** for **TNF-alpha**, binding to it and preventing its interaction with cellular receptors. - By neutralizing **TNF-alpha**, etanercept reduces the inflammation and joint damage associated with **rheumatoid arthritis**. *TGF beta* - **TGF-beta** is a cytokine primarily involved in cell growth, differentiation, and tissue repair, and it generally has an **immunosuppressive role**. - Its mechanism of action is distinct from etanercept, which targets pro-inflammatory pathways. *IL-2* - **IL-2** is a cytokine essential for the proliferation and differentiation of T cells, playing a key role in **adaptive immunity**. - Medications targeting IL-2, such as **daclizumab**, are typically used to prevent transplant rejection or treat certain autoimmune conditions, not rheumatoid arthritis. *IL-6* - **IL-6** is a pro-inflammatory cytokine that contributes significantly to the pathogenesis of rheumatoid arthritis, stimulating acute phase reactants and immune cell activation. - While significant in rheumatoid arthritis, **tocilizumab** (an IL-6 receptor antagonist) targets this pathway, not etanercept.

Q: Which of the following side effects of opioid analgesics is MOST persistent and does NOT improve with tolerance?

Constipation. ***Constipation*** - **Opioid-induced constipation** is a very common and persistent side effect due to activation of **opioid receptors** in the gastrointestinal tract, leading to decreased peristalsis and increased water absorption. - Unlike some other side effects, constipation often does not improve over time with continued opioid use and requires proactive management. *Nausea and Vomiting* - While **nausea and vomiting** are common side effects of opioid analgesics, they tend to be more prevalent when initiating therapy or with rapid dose escalation and often improve over time as tolerance develops. - These symptoms are primarily caused by opioid activation of the **chemoreceptor trigger zone** in the brainstem and increased vestibular sensitivity. *Respiratory Depression* - **Respiratory depression** is a serious and potentially life-threatening side effect of opioid analgesics, characterized by decreased respiratory rate and depth. - It is often dose-dependent and a primary concern in opioid overdose, but it is not as universally or persistently experienced as constipation during routine therapeutic use in non-tolerant individuals. *Sedation* - **Sedation** is a common side effect of opioid analgesics, especially when starting treatment or with dose increases, due to their depressant effects on the central nervous system. - Patients often develop tolerance to the sedative effects over time, meaning it becomes less prominent with continued use, unlike opioid-induced constipation.

Q: Muscle rigidity due to opioids is primarily caused by their effect on which receptor?

mu. ***mu*** - Opioids, by activating **mu-opioid receptors**, particularly in the **brainstem** and **spinal cord**, can cause a phenomenon known as "wooden chest syndrome" or muscle rigidity. - This effect results from increased dopamine turnover in the **nigrostriatal pathway** and is pronounced with rapid intravenous administration of potent opioids like **fentanyl**. *kappa* - **Kappa-opioid receptors** are primarily associated with effects like **dysphoria** [1], **sedation**, and **diuresis**. - While they contribute to some opioid effects, they are not the primary mediators of **muscle rigidity**. *sigma* - The **sigma receptor** is not considered a classical opioid receptor and is not directly involved in the analgesic effects of opioids. - Activation of **sigma receptors** is associated with effects like **dysphoria**, hallucinations, and motor incoordination, but not the specific muscle rigidity caused by opioids. *delta* - **Delta-opioid receptors** play a role in **analgesia** [1], **mood regulation**, and **epileptic seizures**. - They are not directly implicated in the mechanism of **opioid-induced muscle rigidity**.

Q: Which of the following drugs is not typically used in the management of acute gout?

Sulfinpyrazone. ***Sulfinpyrazone*** - Sulfinpyrazone is a **uricosuric agent** used for **long-term management of chronic gout** by increasing uric acid excretion. - It is not indicated for acute gout attacks as it does not directly address the inflammation and pain experienced during an acute flare. *Non-steroidal anti-inflammatory drugs (NSAIDs)* - NSAIDs like **indomethacin** are cornerstone treatments for acute gout, effectively reducing pain and inflammation. - They work by inhibiting **prostaglandin synthesis**, which mediates the inflammatory response. *Colchicine* - Colchicine is used for **acute gout attacks** as it inhibits neutrophil migration and activity, thereby reducing inflammation. - It is most effective when administered within **24 hours of symptom onset**. *Corticosteroids* - Corticosteroids (e.g., prednisone) are effective anti-inflammatory agents used in acute gout, particularly when NSAIDs are contraindicated. - They can be administered orally, intravenously, or via **intra-articular injection** for rapid relief.

Q: What is the classification of the drug Anakinra?

IL-1 antagonist. ***IL-1 antagonist*** - **Anakinra** is a recombinant form of the human **interleukin-1 receptor antagonist (IL-1Ra)**, which competitively inhibits the binding of IL-1 to its receptors. - By blocking IL-1, Anakinra reduces inflammation and tissue damage in conditions like **rheumatoid arthritis** and **systemic juvenile idiopathic arthritis**. *IL-2 antagonist* - **IL-2 antagonists** (e.g., basiliximab, daclizumab) are primarily used as **immunosuppressants** to prevent organ transplant rejection. - They act by blocking the action of **interleukin-2**, a cytokine crucial for T-cell proliferation and activation. *IL-6 antagonist* - **IL-6 antagonists** (e.g., tocilizumab, sarilumab) target the **interleukin-6 receptor**, reducing inflammatory responses driven by IL-6. - These drugs are used in conditions like **rheumatoid arthritis** and **giant cell arteritis**. *IL-10 antagonist* - **IL-10** is generally considered an **anti-inflammatory cytokine** that suppresses immune responses. - Antagonizing IL-10 would likely *promote* inflammation, and there are no widely used clinical drugs that function specifically as IL-10 antagonists.

Q: All of the following are tumor necrosis factor-blocking agents, except:

Abciximab. ***Abciximab*** - **Abciximab** is a **glycoprotein IIb/IIIa receptor antagonist** used as an antiplatelet agent, not a TNF-blocking agent. - It works by preventing the binding of **fibrinogen**, **von Willebrand factor**, and other adhesive proteins to the glycoprotein IIb/IIIa receptor on platelets, thereby inhibiting platelet aggregation. *Adalimumab* - **Adalimumab** is a **monoclonal antibody** that directly binds to **tumor necrosis factor-alpha (TNF-α)**, preventing it from binding to its receptors. - It is used in conditions like **rheumatoid arthritis**, **psoriatic arthritis**, and **Crohn's disease**. *Etanercept* - **Etanercept** is a **fusion protein** that acts as a **decoy receptor** for **TNF-α**, binding to it and rendering it inactive. - It is also indicated for similar autoimmune and inflammatory conditions as adalimumab. *Infliximab* - **Infliximab** is a **chimeric monoclonal antibody** that binds with **high affinity** to both the **soluble and transmembrane forms of TNF-α**. - It neutralizes TNF-α's biological activity and is used in the treatment of diseases such as **Crohn's disease**, **ulcerative colitis**, and **rheumatoid arthritis**.

Q: Sufentanil is classified as a potent:

Analgesic. ***Analgesic*** - **Sufentanil** is a synthetic **opioid analgesic** primarily used for its potent pain-relieving effects, especially in surgical and intensive care settings - It acts by binding to and activating **μ-opioid receptors** in the central nervous system, reducing the perception of pain - Approximately **5-10 times more potent than fentanyl**, making it one of the most potent opioid analgesics available - Commonly used in **anesthesia** for its rapid onset and short duration of action *Myocardial depressant* - While high doses of some anesthetic agents can cause myocardial depression, sufentanil has **minimal direct myocardial depressant effects** in clinically relevant doses - Its primary classification is not as a direct cardiac depressant, although it can cause **bradycardia** and hypotension through **vagal stimulation** and decreased sympathetic tone *Hepatotoxin* - There is **no significant evidence** classifying sufentanil as a hepatotoxin that causes liver damage - Liver toxicity is more commonly associated with drugs like **acetaminophen in overdose** or certain anesthetics like **halothane** - Sufentanil is extensively metabolized by the liver but does not cause hepatotoxicity *Anticonvulsant* - **Sufentanil** does not possess anticonvulsant properties - Opioids generally do not have seizure prevention effects and may occasionally lower the seizure threshold, though this is rare with sufentanil at therapeutic doses - Anticonvulsants are a separate class of drugs (e.g., phenytoin, valproate, levetiracetam) used to prevent or reduce seizures

Question 1

Which of the following opioids can be given intranasally?

Accepted Answer

Butorphanol

Answer

Tramadol

Answer

Pethidine

Answer

Buprenorphine

Question 2

Which of the following drugs is known for its long-acting effects due to enterohepatic circulation?

Accepted Answer

Phenylbutazone

Answer

Sulindac

Answer

Piroxicam

Answer

Aspirin

Question 3

Among NSAIDs, aspirin is unique because it:

Accepted Answer

Irreversibly inhibits its target enzyme

Answer

Reduces fever

Answer

Selectively inhibits COX-1 enzyme

Answer

May reduce the risk of colon cancer

Question 4

Etanercept, used in rheumatoid arthritis, acts by:

Accepted Answer

TNF alpha

Answer

IL-2

Answer

IL-6

Answer

TGF beta

Question 5

Which of the following side effects of opioid analgesics is MOST persistent and does NOT improve with tolerance?

Accepted Answer

Constipation

Answer

Nausea and Vomiting

Answer

Respiratory Depression

Answer

Sedation

Question 6

Muscle rigidity due to opioids is primarily caused by their effect on which receptor?

Accepted Answer

mu

Answer

kappa

Answer

sigma

Answer

delta

Question 7

Which of the following drugs is not typically used in the management of acute gout?

Accepted Answer

Sulfinpyrazone

Answer

Colchicine

Answer

Corticosteroids

Answer

Non-steroidal anti-inflammatory drugs (NSAIDs)

Question 8

What is the classification of the drug Anakinra?

Accepted Answer

IL-1 antagonist

Answer

IL-2 antagonist

Answer

IL-6 antagonist

Answer

IL-10 antagonist

Question 9

All of the following are tumor necrosis factor-blocking agents, except:

Accepted Answer

Abciximab

Answer

Adalimumab

Answer

Infliximab

Answer

Etanercept

Question 10

Sufentanil is classified as a potent:

Accepted Answer

Analgesic

Answer

Myocardial depressant

Answer

Hepatotoxin

Answer

Anticonvulsant

Analgesics and Anti-inflammatory Drugs — MCQs

Analgesics and Anti-inflammatory Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?